Texas Back Institute spine surgeon Richard Guyer concurs, citing results in more than 300 patients at his clinic.

FORBES: On The Cover/Top Stories

Guyer brought up something that he had just heard on the radio.

NEWYORKER: The Hardest Vote

In an interview before the release of the Genentech data, Eyetech chief executive DavidGuyerDavid Guyer emphasized that his drug may have safety advantages over Lucentis--although many of those are still hypothetical.

FORBES: Magazine Article

Hetrick put me in touch with Tom Guyer, Jr.

NEWYORKER: The Hardest Vote

In an interview before the release of the Genentech data, Eyetech chief executive David Guyer emphasized that his drug may have safety advantages over Lucentis--although many of those are still hypothetical.

FORBES: More Eye-Opening Data From Genentech